Holly Vance

Holly Vance is currently the General Counsel at Variant Bio. Prior to this, they were the General Counsel at Neoleukin Therapeutics from October 2020 to November 2021. Before that, they were an Associate General Counsel at the Bill & Melinda Gates Foundation from September 2015 to October 2020, providing legal counsel and strategic guidance across a broad spectrum of areas. Holly began their career as a Partner at K&L Gates in January 2005, where they represented and advised clients in corporate and business matters, including financings, mergers and acquisitions, complex commercial agreements, corporate governance, and securities laws. Holly is experienced in leading and managing cross-border transactions involving jurisdictions in Africa, Asia, and Europe.

Holly Vance has a Juris Doctor from the University of Washington School of Law, a Pharm.D. from the University of Washington, and two Bachelor of Science degrees from the University of Washington - one in Cell & Molecular Biology and the other in Pharmacy.

Holly Vance reports to Andrew Farnum, CEO. Holly Vance works with Kaja Wasik - Chief Science Officer, Gregory Tranah - VP, Medical Biology, and Alon Keinan - Senior Director, Population Genetics.